Table 4.

Heart failure outcome trials completed in 2020: comparison of active vs. placebo group

EMPEROR-reduced [30]		SOLOIST-WHF [31]
Class & Cardiovascular outcomes	HR (95.6% CI) p-value	Class & Cardiovascular outcomes	HR (95.6% CI) p-value
Primary composite outcome Composite of CV death or hospitalisation for HF	0.75 (0.65–0.86) p < 0.001	Primary composite outcome Total occurrences of CV death, HHF, and urgent visits for HF	0.67 (0.52–0.85) p < 0.001
Secondary outcome Total no. of hospitalisations for HF	0.70 (0.58–0.85) p < 0.001	Secondary outcome Total occurrence of HF events	0.64 (0.49–0.83) p < 0.001
Secondary outcome Mean slope of change in eGFR — ml/min/1.73 m2 per year	1.73 (1.10–2.37) p < 0.001	Secondary outcome CV death	0.84 (0.58–1.22) p = 0.36
Other prespecified analyses Composite kidney outcome	0.50 (0.32–0.77)	Secondary outcome 3P-Mace and HHF events	0.72 (0.56–0.92)
Other prespecified analyses No. of hospitalisation for any cause	0.85 (0.75–0.95)	Secondary outcome All-cause mortality	0.82 (0.59–1.14)
Other prespecified analyses All-cause death	0.92 (0.77–1.10)

Adverse events	Event rate (%) active vs. placebo group	Adverse events	Event rate (%) active vs. placebo group
Worsening renal function	3.2 vs. 5.1	Diarrhea	6.1 vs. 3.4
Genital tract infections	1.7 vs. 0.6	Severe hypoglycaemia	1.5 vs. 0.3
Hypotension	9.4 vs. 8.7	Hypotension	6.0 vs. 4.6